Madrid native appointed new GM at major US vaccine company after leaving rivals

Madrid native appointed new GM at major US vaccine developer after leaving rival company. Image: David Jimenez/Linkedin

A NATIVE of Spain’s Madrid has been appointed the US General Manager of one of the world’s most prominent vaccine developers – after leaving a rival company.

On Thursday, November 17, it was announced that Madrid native David Jimenez has been appointed as the general manager of US-based Moderna.

“Moderna, Inc, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of David Jiménez as General Manager, United States, effective November 21, 2022,” the company said.

“Mr Jiménez will be responsible for commercial efforts in the United States, reporting to Arpa Garay, Moderna’s Chief Commercial Officer.”

Arpa Garay said about the appointment: “David has significant experience in leading major pharmaceutical franchises and bringing transformational products to patients.

“His expertise will be invaluable as we transition to a commercial vaccine market in the U.S., and as we work to advance new candidates in 2023 and beyond. I’m excited to collaborate with him during this pivotal time for our business.”

As noted, Jiménez joins from one of Moderna’s major competitors.

“Prior to Moderna, Mr Jiménez spent two decades at Johnson & Johnson in a variety of leadership roles in the Medical Devices, Consumer Health and Pharmaceutical sectors, across four continents,” the Moderna statement continued.

“In his most recent role, Mr Jiménez served as President for Janssen Immunology, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, leading the unit’s $10+ billion U.S. Immunology franchise.”

He was appointed to that role in January 2022.

“He also previously led Janssen’s Pulmonary Hypertension U.S. organisation, for in-market brands, including two which achieved blockbuster status under his leadership,” it added.

“Mr Jiménez is a pharmacist, with a Doctorate in Pharmacy from the University of Alcala and a Master of Business Administration from the Instituto de Empresa, both in Madrid.

“He also recently completed the Advance Management Program at Harvard Business School in Boston.”

Speaking about his appointment at Moderna, the Madrid native said: “I’ve long admired Moderna for both their pioneering approach to mRNA technology and ability to rapidly advance science to bring transformative medicines to patients.

“This is already a terrific organization, with a talented and growing commercial team in the U.S., and a highly impactful vaccine that continues to play a significant role in addressing the COVID-19 pandemic. I am thrilled to be joining Moderna and look forward to expanding its presence within the U.S.”


Thank you for taking the time to read this article, do remember to come back and check The Euro Weekly News website for all your up-to-date local and international news stories and remember, you can also follow us on Facebook and Instagram.

FacebookTwitterRedditWhatsAppTelegramLinkedInEmailCopy Link
Go Back
Written by

Matthew Roscoe

Originally from the UK, Matthew is based on the Costa Blanca and is a web reporter for The Euro Weekly News covering international and Spanish national news. Got a news story you want to share? Then get in touch at [email protected]

Comments


    • Dr Trth

      17 November 2022 • 16:10

      He can’t wait to get producing more vaccines to control the mRNA of healthy human beings to fill their pockets with more taxpayers money. Have the general public lost their minds? dumbed down to the hilt whilst healthy people are health compromised by these “test medical” vaccines.

      Reply
    • Jessica

      17 November 2022 • 17:55

      I don´t think that working for any of these unethical companies is anything to boast about. They have brought about the worst injuries to the general public ever created by so called medicine

      Reply

    Leave a comment

    Your email address will not be published. Required fields are marked *